Manifestations of hyperprolactinoma and its management by bromocriptine and cabergoline

Abstract EN

This is a prospective study analyzing gender differences in the presentation of hyperprolactinemia as well as the efficacy and tolerance to cabergoline and bromocriptine.

Thirty-six patients (23 women, 13 men) were recruited and divided into two groups; Group One received bromocriptine and Group Two received cabergoline for three months.

The prolactin level was measured before and after treatment in both groups.

Galactorrhea and infertility were more common symptoms in women ; however, 100 % of men with micro or macroprolactinoma had libido disturbances.

The prolactin level was higher in men than in women whether they exhibited macro (7640 ± 80 vs.

6230 ± 71ng / mL) or microprolactinomas (6167 ± 895 vs.

5998 ± 775 ng / mL).

The prolactin level was significantly higher in women with non-tumor hyperprolactinemia (3390 ± 164 vs.

1279 ± 53, p = 0.038).

The mean serum prolactin level was significantly decreased in both groups whether they received bromocriptine or cabergoline (5790 ± 370 vs.

2725 ± 124 ng / mL ; p = 0.001).

The prolactin reduction was more prominent in the cabergoline group whether in men or women, than in the bromocriptine group at the end of the three months of treatment (5791 ± 723 vs.

1725 ± 318 ng / mL ; p = 0.001).